Categories of novel therapies for acute myeloid leukemia (AML).
| Abbreviations: IL, interleukin; GM-CSF, granulocyte-macrophage colony-stimulating factor |
| Drug-resistance modifiers |
| Proteosome inhibitors |
| Pro-apoptotic approaches |
| Signal transduction inhibitors |
| “RAS”-targeted (e.g., farnesyl transferase inhibitors) |
| Tyrosine kinase targeted (e.g., FLT3, c-kit) |
| Downstream signal inhibitors |
| Immunotherapeutic approaches |
| Antigens known |
| anti-CD33 |
| anti-GM-CSF receptor |
| Antigens unknown |
| stimulate immune system (IL-2, GM-CSF) |
| present tumor antigens effectively |
| dendritic cell fusion |
| transfer hematopoietic growth factor genes |
| Abbreviations: IL, interleukin; GM-CSF, granulocyte-macrophage colony-stimulating factor |
| Drug-resistance modifiers |
| Proteosome inhibitors |
| Pro-apoptotic approaches |
| Signal transduction inhibitors |
| “RAS”-targeted (e.g., farnesyl transferase inhibitors) |
| Tyrosine kinase targeted (e.g., FLT3, c-kit) |
| Downstream signal inhibitors |
| Immunotherapeutic approaches |
| Antigens known |
| anti-CD33 |
| anti-GM-CSF receptor |
| Antigens unknown |
| stimulate immune system (IL-2, GM-CSF) |
| present tumor antigens effectively |
| dendritic cell fusion |
| transfer hematopoietic growth factor genes |